0.30
0.0081 (2.77%)
0.0081 (2.77%)
Upgrade to Real-Time
Premarket
| Volume | 100 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Galmed Pharmaceuticals Ltd | GLMD | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.0081 | 2.77% | 0.30 | 08:05:48 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.2919 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 1 | 100 | - | 0.29 - 2.6899 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 08:05:48 | formt | 100 | $ 0.30 | USD |
Period:
Draw Mode:
Galmed Pharmaceuticals Ltd Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 6.33M | 21.11M | 21.70M | $ - | $ - | -1.32 | -0.40 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | - | - |
Galmed Pharmaceuticals News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical GLMD Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.31 | 0.33 | 0.29 | 0.3005082 | 26,098 | -0.01 | -3.23% |
| 1 Month | 0.39 | 0.41 | 0.29 | 0.3301212 | 33,108 | -0.09 | -23.08% |
| 3 Months | 0.4349 | 0.49 | 0.29 | 0.3757414 | 37,699 | -0.1349 | -31.02% |
| 6 Months | 0.5121 | 0.75 | 0.29 | 0.4851452 | 70,415 | -0.2121 | -41.42% |
| 1 Year | 2.58 | 2.6899 | 0.29 | 1.10 | 94,100 | -2.28 | -88.37% |
| 3 Years | 4.68 | 7.38 | 0.29 | 3.32 | 151,726 | -4.38 | -93.59% |
| 5 Years | 8.06 | 27.06 | 0.29 | 7.26 | 165,321 | -7.76 | -96.28% |
Galmed Pharmaceuticals Description
| Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis. |